June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Recurrence of macular edema after intravitreal bevacizumab injection in eyes with macular edema secondary to retinal vein occlusion
Author Affiliations & Notes
  • young gyun Kim
    Eulji medical center, Seoul, Republic of Korea
  • Ji young Moon
    Eulji medical center, Seoul, Republic of Korea
  • Kyung Hoon Seo
    Kyung Hee hospital, Seoul, Republic of Korea
  • Seung yong Lee
    Eulji University Hospital, Daejeon, Republic of Korea
  • Eung Suk Kim
    Eulji University Hospital, Daejeon, Republic of Korea
  • Seung young Yu
    Kyung Hee hospital, Seoul, Republic of Korea
  • Hyung woo Kwak
    Kyung Hee hospital, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships young gyun Kim, None; Ji young Moon, None; Kyung Hoon Seo, None; Seung yong Lee, None; Eung Suk Kim, None; Seung young Yu, None; Hyung woo Kwak, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1950. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      young gyun Kim, Ji young Moon, Kyung Hoon Seo, Seung yong Lee, Eung Suk Kim, Seung young Yu, Hyung woo Kwak; Recurrence of macular edema after intravitreal bevacizumab injection in eyes with macular edema secondary to retinal vein occlusion. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1950.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The purpose of this study is to find out the incidence of recurred macular edema after the intravitreal bevacizumab injection and related factors which affects the recurrence of macular edema during the 6 months’ follow-up.

Methods: Intravitreal bevacizumab injection was performed in 73 eyes of 73 patients who had macular edema with RVO. Best corrected visual acuity (BCVA) and central macular thickness (CMT) were checked for 6 months after the injection. Recurrence was defined as a 30% increase in CMT after an initial decrease of CMT. Factors that differed between the recurred group and the non-recurred group were identified.

Results: Recurrence occurred in 38 of 73 eyes (49.4%) and the mean time between injection and recurrence was 15.2 weeks. The mean interval between the onset and the initiation of intravitreal bevacizumab injection was 3.42 weeks in the recurred group, which showed a significant difference compared to the non-recurred group(P<0.05). Also, a greater decrease in CMT 1 week after injection was associated with a decrease in recurrence(P<0.05). Other than those, age, gender, the patients’ comorbidity, whether the consecutive bevacizumab injection was performed or not after resolution of macular edema, the number of injection, pre-treatment BCVA and CMT were not associated with recurrence.

Conclusions: Recurrence rate was very high after intravitreal bevacizumab injection in eyes with macular edema secondary to RVO. To avoid recurrence, injection can be recommended to initiate at least 4 weeks after the onset. A better prognosis can be expected in patients whose CMT decreases greatly from baseline after 1 week of treatment.

Keywords: 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×